iBionext
VC Fund
Paris, France
iBionext is a unique healthcare fund created within a proven breakthrough innovation accelerator. Their companies are based in a single location named “Passage de l’innovation” in Paris, France. Over the past 4 years, we have created 7 companies that have raised over 250M € and created 103 highly qualified jobs.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 36%
- Fund size:
- $113M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries iBionext invests in
Medical DeviceArtificial IntelligenceDronesGamingMobile
Stages iBionext invests in
Venture - Series UnknownSeries ASeries BSeedSeries C
Countries iBionext invests in
France
Round sizes
Series A $8.2M–$15MSeries B $15M–$39MVenture - Series Unknown $2.7M–$14M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $8.2M–$15M
- Series B
- $15M–$39M
- Venture - Series Unknown
- $2.7M–$14M
Investment Focus
Industry
- Medical Device 2 (14%)
- Artificial Intelligence 2 (14%)
- Drones 1 (7%)
- Gaming 1 (7%)
- Mobile 1 (7%)
Stage
- Venture - Series Unknown 3 (21%)
- Series A 2 (14%)
- Series B 2 (14%)
- Seed 1 (7%)
- Series C 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexia Perouse
Co-Founder & CEO
|
Co-Founder & CEO | Total investments: 13 | Find email | |
Bernard Gilly
Founder & Chairman
|
Founder & Chairman | Total investments: 4 | Find email | |
Christophe Bancel
VENTURE PARTNER
|
VENTURE PARTNER | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BrainEver’s innovative therapeutic strategy is a translation of the work by Alain Prochiantz and colleagues on brain development and physiology. They demonstrated that homeoproteins, first identified as early developmental regulators, are also active throughout life and control several neuronal functions, including metabolism and epigeneticstability.BrainEver makes the hypothesis that, in patients, homeoprotein administration could durably modify the physiological resistance of surviving neurons while increasing their activity, thus leading to the improvement of clinical symptoms.Different homeoproteins that could be important in different neurodegenerative pathologies are being explored, the most advanced being Engrailed 1 (BREN01) for the treatment of Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS).Beside Engrailed 1 in Parkinson Disease and ALS, BrainEver is currently generating a pipeline of 4 drug candidates targeting other neurodegenerative disease like Huntington Disease and Optic Neuropathies. | $38.8M / Series B / Jul 03, 2025 | ||
| Tilak is a unique videogame studio where like-minded & passionate people create fun mobile medical games to monitor patients with chronic diseases. | $11M / Oct 12, 2023 | ||
| Tilak is a unique videogame studio where like-minded & passionate people create fun mobile medical games to monitor patients with chronic diseases. | $10.5M / Series A / Oct 12, 2023 | ||
| Prophesee is the inventor of the world’s most advanced neuromorphic vision systems.Prophesee’s patented sensors and AI algorithms, introduce a new computer vision paradigm based on how the human eye and brain work. Like the human vision, it sees events: essential, motion information in the scene, not a succession of images.This Metavision®method allows for unprecedented speed (>10 000fps time resolution equivalent), dynamic range (>120dB), data volume (10x to 1000x less) and power efficiency (<10 mW). Prophesee bio-inspired revolution opens a new path to absolute efficiency and safety in autonomous driving, Mobile, IoT and Industry 4.0.Prophesee was founded within iBionext Start-up Studio (Paris) in 2014 by Ryad Benosman, Bernard Gilly, Christoph Posch and Luca Verre. The quartet brings a strong combination of experience in image sensing, neuromorphic computing, VLSI design, entrepreneurship and business development. Prophesee is based in Paris, with local offices in Grenoble, Shanghai, Tokyo and Silicon Valley. The company is driven by a team of more than 100 visionary engineers, holds more than 50 international patents and is backed by leading international equity and corporate investors including 360 Capital Partners, European Investment Bank, iBionext, Inno-Chip, Intel Capital, Renault Group, Robert Bosch Venture Capital, Sinovation, Supernova Invest, Xiaomi. | $47.5M / Series C / Sep 22, 2022 | ||
| Tilak is a unique videogame studio where like-minded & passionate people create fun mobile medical games to monitor patients with chronic diseases. | $8.2M / Series A / Oct 28, 2021 | ||
| GrAI Matter Labs (GML) is in the business of life-ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. GrAI Matter Labs delivers brain-inspired chips that behave like humans do. That make machines assisting humans act, and react, in real time, live. Which optimizes energy and maximizes efficiency, saving time,money, and vital natural resources. Welcome to a AI-ready future, where robots, drones, autonomous vehicles, AR devices, surveillance cameras are smart, safe and convenient. Welcome to an optimized future. | $14M / Venture - Series Unknown / Nov 23, 2020 | ||
| Chronolife is developing a unique solution capable of constant monitoring of multiple physiological parameters simultaneously that makes predictions based on big data analysis in real-time. Thanks to its disruptive proprietary algorithm, named HOTS (Hierarchy of Event-Based Time Surfaces), Chronolife aims to create a paradigm shift in themanagement of patients with chronic conditions. The company has chosen to initially target two major indications that affect a large number of patients worldwide: Heart Failure and Epilepsy. | Seed / Dec 12, 2019 | ||
| Prophesee is the inventor of the world’s most advanced neuromorphic vision systems.Prophesee’s patented sensors and AI algorithms, introduce a new computer vision paradigm based on how the human eye and brain work. Like the human vision, it sees events: essential, motion information in the scene, not a succession of images.This Metavision®method allows for unprecedented speed (>10 000fps time resolution equivalent), dynamic range (>120dB), data volume (10x to 1000x less) and power efficiency (<10 mW). Prophesee bio-inspired revolution opens a new path to absolute efficiency and safety in autonomous driving, Mobile, IoT and Industry 4.0.Prophesee was founded within iBionext Start-up Studio (Paris) in 2014 by Ryad Benosman, Bernard Gilly, Christoph Posch and Luca Verre. The quartet brings a strong combination of experience in image sensing, neuromorphic computing, VLSI design, entrepreneurship and business development. Prophesee is based in Paris, with local offices in Grenoble, Shanghai, Tokyo and Silicon Valley. The company is driven by a team of more than 100 visionary engineers, holds more than 50 international patents and is backed by leading international equity and corporate investors including 360 Capital Partners, European Investment Bank, iBionext, Inno-Chip, Intel Capital, Renault Group, Robert Bosch Venture Capital, Sinovation, Supernova Invest, Xiaomi. | $28M / Series C / Oct 28, 2019 | ||
| Prophesee is the inventor of the world’s most advanced neuromorphic vision systems.Prophesee’s patented sensors and AI algorithms, introduce a new computer vision paradigm based on how the human eye and brain work. Like the human vision, it sees events: essential, motion information in the scene, not a succession of images.This Metavision®method allows for unprecedented speed (>10 000fps time resolution equivalent), dynamic range (>120dB), data volume (10x to 1000x less) and power efficiency (<10 mW). Prophesee bio-inspired revolution opens a new path to absolute efficiency and safety in autonomous driving, Mobile, IoT and Industry 4.0.Prophesee was founded within iBionext Start-up Studio (Paris) in 2014 by Ryad Benosman, Bernard Gilly, Christoph Posch and Luca Verre. The quartet brings a strong combination of experience in image sensing, neuromorphic computing, VLSI design, entrepreneurship and business development. Prophesee is based in Paris, with local offices in Grenoble, Shanghai, Tokyo and Silicon Valley. The company is driven by a team of more than 100 visionary engineers, holds more than 50 international patents and is backed by leading international equity and corporate investors including 360 Capital Partners, European Investment Bank, iBionext, Inno-Chip, Intel Capital, Renault Group, Robert Bosch Venture Capital, Sinovation, Supernova Invest, Xiaomi. | $27.2M / Series B / Oct 28, 2019 | ||
| GrAI Matter Labs (GML) is in the business of life-ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. GrAI Matter Labs delivers brain-inspired chips that behave like humans do. That make machines assisting humans act, and react, in real time, live. Which optimizes energy and maximizes efficiency, saving time,money, and vital natural resources. Welcome to a AI-ready future, where robots, drones, autonomous vehicles, AR devices, surveillance cameras are smart, safe and convenient. Welcome to an optimized future. | $15M / Series A / Apr 12, 2018 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
117,441 investors
Health Care Investors
48,627 investors
Marketplace Investors
48,297 investors
Hardware Investors
46,079 investors
Artificial intelligence Investors
45,634 investors
Consumer Investors
37,868 investors
Gaming Investors
32,180 investors
Mobile Investors
15,046 investors
Medical Device Investors
12,432 investors
FAQ
What does iBionext invest in?
iBionext invests primarily in Medical Device, Artificial Intelligence and Drones startups, most often at Venture - Series Unknown and Series A stage. Most of the 14 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is iBionext's check size?
iBionext typically joins rounds of $8.2M–$15M at Series A, $15M–$39M at Series B and $2.7M–$14M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds iBionext participates in.
How do I contact iBionext?
Public channels for iBionext include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at iBionext?
The team at iBionext includes Alexia Perouse (Co-Founder & CEO), Bernard Gilly (Founder & Chairman) and Christophe Bancel (VENTURE PARTNER). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
